查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1468506

2024-2032 年按藥物類別（多奈哌齊、加蘭他敏、卡巴拉汀、美金剛等）、配銷通路（醫院藥房、零售藥房、網路商店等）和地區分類的阿茲海默症藥物市場報告

Alzheimer's Drugs Market Report by Drug Class (Donepezil, Galantamine, Rivastigmine, Memantine, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores, and Others), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年，全球阿茲海默症藥物市場規模達77億美元。阿茲海默症盛行率的上升、藥物開發的眾多進步以及神經退化性疾病研究的公共和私人資金的增加是推動市場的一些主要因素。

阿茲海默症藥物是指專門用於減輕阿茲海默症症狀或減緩其進展的藥物化合物和療法，阿茲海默症是一種常見的神經退化性疾病，主要影響認知功能。他們的目標是解決大腦中潛在的病理生理變化，例如澱粉樣蛋白斑塊和 tau 蛋白纏結的積累，這是阿茲海默症的特徵。它們分為兩大類，包括膽鹼酯酶抑制劑和 NMDA 受體拮抗劑。膽鹼酯酶抑制劑，如多奈哌齊、卡巴拉汀和加蘭他敏，透過提高大腦中神經傳導物質的水平來發揮作用，暫時增強認知功能。 NMDA 受體拮抗劑（例如美金剛）可調節麩胺酸活性，有助於緩解認知和行為症狀。

阿茲海默症的盛行率不斷上升，需要有效的治療，這將刺激預測期內阿茲海默症藥物市場的成長。此外，由於神經科學的許多進步以及對疾病潛在機制的更深入了解，主要參與者不斷加強研究和開發力度，從而發現了潛在的治療藥物，這對市場成長產生了積極影響。此外，政府和組織對神經退化性疾病研究的資金分配增加，為藥物開發創造了有利的環境，從而促進了市場成長。除此之外，不斷擴大的老化人口（特別是在已開發地區）正在推動市場成長，因為老年人更容易罹患阿茲海默症。此外，新藥和療法的法規核准不斷增加，為製藥公司進入和擴大業務創造了機會，也促進了市場成長。

阿茲海默症藥物市場趨勢/促進因素：

該疾病盛行率上升

阿茲海默症患者病率不斷上升是支持市場成長的關鍵因素之一。這可以歸因於全球人口快速老化。隨著人們壽命的延長，包括阿茲海默症在內的與年齡相關的神經退化性疾病的發生率激增。這種人口結構的變化給全球醫療保健系統帶來了不斷增加的負擔，因此需要有效的治療。製藥公司正在透過投資開發可以緩解症狀或可能減緩疾病進展的藥物來滿足這一需求。此外，隨著更多病例的發現，認知的提高和早期診斷也導致盛行率上升。因此，患病率因素推動了市場，並強調了迫切需要研究和創新來解決阿茲海默症帶來的醫療保健挑戰。

研究進展迅速

在分子和細胞層面對阿茲海默症的理解的進步是市場的關鍵驅動力。研究人員正在揭示疾病背後的複雜機制，包括澱粉樣蛋白斑塊和 tau 蛋白纏結在大腦退化中的作用。這些見解為藥物開發提供了有價值的目標。此外，遺傳學研究揭示了增加阿茲海默症易感性的遺傳因素，進一步指導了藥物發現工作。基因組學、神經影像學和生物標記分析等尖端技術正在促進臨床試驗和藥物療效評估。這些研究驅動的發展有助於擴大潛在阿茲海默症藥物的種類並提高其有效性，為改善患者的治療結果帶來希望。

增加政府資金和支持

全球各國政府和醫療機構越來越意識到阿茲海默症是一場公共衛生危機。該疾病造成的巨大經濟和社會影響，包括護理人員負擔和醫療費用，導致阿茲海默症研究和藥物開發計劃的資金增加。對製藥公司的政府資助、研究合作和激勵措施變得更加普遍。這筆資金支持了正在進行的研究工作，並鼓勵製藥業投資阿茲海默症藥物開發。此外，監管機構正在簡化阿茲海默症藥物的核准流程，促進更快的市場進入。在這種公共和私營部門支持的協作環境中，製藥公司受到激勵進行創新，並將有效的阿茲海默症治療推向市場，以滿足緊迫的全球醫療保健需求。

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球阿茲海默症藥物市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依藥物類別

  • 多奈哌齊
    • 市場走向
    • 市場預測
  • 加蘭他敏
    • 市場走向
    • 市場預測
  • 卡巴拉汀
    • 市場走向
    • 市場預測
  • 美金剛
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 7 章：市場區隔：按配銷通路

  • 醫院藥房
    • 市場走向
    • 市場預測
  • 零售藥房
    • 市場走向
    • 市場預測
  • 網路商店
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 9 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 10 章：價值鏈分析

第 11 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 12 章：價格分析

第13章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbvie Inc.
    • AstraZeneca PLC
    • Biogen Inc.
    • Daiichi Sankyo Company Limited
    • Eisai Co. Ltd.
    • Eli Lilly and Company
    • H. Lundbeck A/S
    • F. Hoffmann-La Roche AG
    • Merck & Co. Inc.
    • Novartis AG
    • Ono Pharmaceutical Co. Ltd.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Limited
Product Code: SR112024A2695

The global Alzheimer's drugs market size reached US$ 7.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5.3% during 2024-2032. The rising prevalence of Alzheimer's disease, numerous advancements in drug development, and increasing public and private funding for neurodegenerative disease research are some of the major factors propelling the market.

Alzheimer's drugs refer to pharmaceutical compounds and therapies specifically designed to mitigate the symptoms or slow the progression of Alzheimer's disease, a prevalent neurodegenerative disorder that primarily affects cognitive functions. They aim to address the underlying pathophysiological changes in the brain, such as the accumulation of amyloid plaques and tau tangles, which are characteristic of Alzheimer's disease. They fall into two main categories, including cholinesterase inhibitors and NMDA receptor antagonists. Cholinesterase inhibitors, like donepezil, rivastigmine, and galantamine, work by boosting the levels of neurotransmitters in the brain, enhancing cognitive function temporarily. NMDA receptor antagonists, such as memantine, regulate glutamate activity, aid in providing relief from cognitive and behavioral symptoms.

The rising prevalence of Alzheimer's disease that necessitates effective treatments will stimulate the growth of the Alzheimer's drugs market during the forecast period. Moreover, the increasing research and development efforts by key players due to numerous advancements in neuroscience and a deeper understanding of the disease's underlying mechanisms, leading to the discovery of potential therapeutic agents, is positively influencing market growth. Additionally, the rise in funding allocations by governments and organizations for neurodegenerative disease research, facilitating a conducive environment for drug development, has catalyzed market growth. Besides this, the expanding aging population, particularly in developed regions, is propelling market growth as the elderly are more susceptible to Alzheimer's disease. Furthermore, the escalating regulatory approvals for novel drugs and therapies that creates opportunities for pharmaceutical companies to enter and expand their presence is contributing to market growth.

Alzheimer's Drugs Market Trends/Drivers:

Rising prevalence of the disease

The escalating prevalence of Alzheimer's disease is one of the key factors supporting the market growth. This can be attributed to the rapidly aging population worldwide. As people live longer, the incidence of age-related neurodegenerative disorders, including Alzheimer's, has surged. This demographic shift places an ever-increasing burden on global healthcare systems and necessitates effective treatments. Pharmaceutical companies are responding to this demand by investing in the development of drugs that can alleviate symptoms or potentially slow down disease progression. Moreover, heightened awareness and early diagnosis contribute to the rising prevalence as more cases are identified. As a result, the prevalence factor drives the market and underscores the urgent need for research and innovation to address the healthcare challenges posed by Alzheimer's disease.

Rapid advancements in research

Advances in the understanding of Alzheimer's disease at the molecular and cellular levels are pivotal drivers in the market. Researchers are unraveling the complex mechanisms behind the disease, including the role of amyloid plaques and tau protein tangles in brain degeneration. These insights provide valuable targets for drug development. Additionally, genetics research is revealing the hereditary factors that increase susceptibility to Alzheimer's, further guiding drug discovery efforts. Cutting-edge technologies, such as genomics, neuroimaging, and biomarker analysis, are facilitating clinical trials and drug efficacy assessments. These research-driven developments are instrumental in expanding the repertoire of potential Alzheimer's drugs and enhancing their effectiveness, offering hope for improved patient outcomes.

Increasing government funding and support

Governments and healthcare organizations across the globe are increasingly recognizing Alzheimer's disease as a public health crisis. The substantial economic and social impact of the disease, including caregiver burden and healthcare costs, has led to a rise in funding for Alzheimer's research and drug development initiatives. Government grants, research partnerships, and incentives for pharmaceutical companies have become more prevalent. This financial support bolsters ongoing research efforts and encourages the pharmaceutical industry to invest in Alzheimer's drug development. Moreover, regulatory agencies are streamlining approval processes for Alzheimer's drugs, facilitating faster market entry. In this collaborative environment of public and private sector support, pharmaceutical companies are incentivized to innovate and bring effective Alzheimer's treatments to the market, addressing a pressing global healthcare need.

Alzheimer's Drugs Industry Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global Alzheimer's drugs market report, along with forecasts at the global, regional and country levels for 2024-2032. Our report has categorized the market based on drug class and distribution channel.

Breakup by Drug Class:

Donepezil

Galantamine

Rivastigmine

Memantine

Others

Donepezil represents the most popular drug class

The report has provided a detailed breakup and analysis of the market based on the drug class. This includes donepezil, galantamine, rivastigmine, memantine, and others. According to the report, donepezil represented the largest segment.

Donepezil is a medication categorized as a cholinesterase inhibitor, commonly used in the treatment of Alzheimer's disease. It works by increasing the levels of certain neurotransmitters in the brain, helping to improve cognitive function and alleviate some of the symptoms associated with Alzheimer's, such as memory loss, confusion, and problems with thinking and reasoning.

Furthermore, donepezil, along with similar drugs like rivastigmine and galantamine, plays a pivotal role in driving the market growth. These drugs are often prescribed to patients with Alzheimer's to manage their symptoms, providing relief and enhancing their quality of life. As the global prevalence of Alzheimer's continues to rise, there is an increasing demand for such drugs. This growing demand encourages pharmaceutical companies to invest in research and development, striving to innovate and improve upon existing treatments, thus contributing to the expansion of the Alzheimer's drugs market.

Breakup by Distribution Channel:

Hospital Pharmacy

Retail Pharmacy

Online Stores

Others

Hospital pharmacy accounts for the majority of the market share

A detailed breakup and analysis of the market based on the distribution channel has also been provided in the report. This includes hospital pharmacy, retail pharmacy, online stores, and others. According to the report, hospital pharmacy accounted for the largest market share.

Hospital pharmacy refers to the specialized pharmacy practice within healthcare institutions, such as hospitals and medical centers. Its primary role is to ensure the safe and effective use of medications for inpatients and outpatients. Hospital pharmacists work closely with healthcare teams to provide medication therapy management, including drug dispensing, monitoring, and patient education. Hospital pharmacies play a crucial role in fueling the market expansion as they are instrumental in the distribution and administration of Alzheimer's medications. They serve as a pivotal link between pharmaceutical companies, healthcare providers, and patients, ensuring that Alzheimer's drugs reach the right individuals at the right time.

Moreover, hospital pharmacists contribute to patient education and adherence, optimizing the effectiveness of these drugs. The growth of the Alzheimer's drugs market is related to the efficient and patient-focused services provided by hospital pharmacies, as they facilitate the delivery of these vital medications to those in need.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance in the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest share in the market since the region has a significant and growing geriatric population, and Alzheimer's primarily affects older individuals. This demographic trend increases the demand for Alzheimer's drugs. Moreover, North America boasts a robust healthcare infrastructure, which includes advanced research facilities and pharmaceutical companies at the forefront of Alzheimer's drug development. These companies conduct clinical trials and research initiatives that contribute to innovation in the field.

Additionally, regulatory bodies like the FDA in the United States play a crucial role in drug approvals, setting the standard for global markets. Apart from this, North America has a high level of awareness about Alzheimer's disease, leading to early diagnosis and greater use of available treatments. Furthermore, North America's well-established healthcare reimbursement systems and patient advocacy groups actively support access to Alzheimer's drugs, fostering an environment that drives market growth and encourages pharmaceutical innovation in the region.

Competitive Landscape:

Key players in the Alzheimer's drugs industry have been instrumental in driving recent innovations. Notably, a groundbreaking FDA-approved drug from one of these major pharmaceutical companies directly targets amyloid plaques, marking a significant advancement in Alzheimer's treatment. Other key players are pioneering therapies that enhance amyloid clearance and simultaneously address tau pathology, both of which have shown promise in clinical trials. Beyond traditional drug development, these companies are exploring innovative approaches, including anti-inflammatory drugs, to combat neuroinflammation associated with Alzheimer's. Additionally, digital health technologies have been integrated into their strategies, with the introduction of cognitive assessment tools and digital biomarkers, revolutionizing early detection and monitoring of Alzheimer's. The efforts of these industry players signify a dynamic and comprehensive approach to tackle this complex neurodegenerative disease.

The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AbbVie Inc.

AstraZeneca PLC

Biogen Inc.

Daiichi Sankyo Company Limited

Eisai Co. Ltd.

Eli Lilly and Company

H. Lundbeck A/S

F. Hoffmann-La Roche AG

Merck & Co. Inc.

Novartis AG

Ono Pharmaceutical Co. Ltd.

Pfizer Inc

Teva Pharmaceutical Industries Limited

Recent Developments:

In July 2023, AbbVie Inc., a leading global biopharmaceutical company, announced the expansion of its strategic collaboration with Calibr, a nonprofit drug discovery division of Scripps Research. This collaboration aims to propel the development of multiple preclinical and early-stage clinical assets in the field of biopharmaceuticals. Building upon their existing partnership, this expansion signifies a commitment to advancing innovative therapies for various diseases.

In March 2021, Biogen Inc. and Eisai Co., Ltd. expanded their existing collaboration agreement on the treatments of Alzheimer's disease. This expansion underscores their shared commitment to addressing one of the most challenging and pressing healthcare issues of our time. Both companies bring unique strengths to the table: Biogen's expertise in neuroscience and drug development, combined with Eisai's deep-rooted knowledge in the field of dementia and Alzheimer's disease, creates a powerful synergy.

In September 2022, Eisai Co., Ltd. and Biogen Inc. reported positive topline results from their global Phase 3 Clarity AD clinical trial of lecanemab. Lecanemab is an investigational antibody designed to target amyloid beta (AB) protofibrils, and it holds promise as a potential treatment for individuals with mild cognitive impairment (MCI) due to Alzheimer's disease and mild Alzheimer's disease. This development marks a significant milestone in the pursuit of effective Alzheimer's treatments. The positive results suggest that lecanemab has shown potential in addressing the underlying pathology of Alzheimer's disease by targeting AB protofibrils, which are thought to contribute to disease progression.

Key Questions Answered in This Report:

  • How has the global alzheimer's drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global alzheimer's drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global alzheimer's drugs market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Alzheimer's Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Donepezil
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Galantamine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Rivastigmine
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Memantine
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Stores
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Abbvie Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 AstraZeneca PLC
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Biogen Inc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Daiichi Sankyo Company Limited
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Eisai Co. Ltd.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Eli Lilly and Company
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 H. Lundbeck A/S
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 F. Hoffmann-La Roche AG
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 SWOT Analysis
    • 13.3.9 Merck & Co. Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Novartis AG
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Ono Pharmaceutical Co. Ltd.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis
    • 13.3.12 Pfizer Inc.
      • 13.3.12.1 Company Overview
      • 13.3.12.2 Product Portfolio
      • 13.3.12.3 Financials
      • 13.3.12.4 SWOT Analysis
    • 13.3.13 Teva Pharmaceutical Industries Limited
      • 13.3.13.1 Company Overview
      • 13.3.13.2 Product Portfolio
      • 13.3.13.3 Financials
      • 13.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Alzheimer's Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Alzheimer's Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Alzheimer's Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 4: Global: Alzheimer's Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 5: Global: Alzheimer's Drugs Market: Breakup by Region (in %), 2023
  • Figure 6: Global: Alzheimer's Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 7: Global: Alzheimer's Drugs (Donepezil) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Alzheimer's Drugs (Donepezil) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Alzheimer's Drugs (Galantamine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Alzheimer's Drugs (Galantamine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Alzheimer's Drugs (Rivastigmine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Alzheimer's Drugs (Rivastigmine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Alzheimer's Drugs (Memantine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Alzheimer's Drugs (Memantine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Alzheimer's Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Alzheimer's Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Alzheimer's Drugs (Hospital Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Alzheimer's Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Alzheimer's Drugs (Retail Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Alzheimer's Drugs (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Alzheimer's Drugs (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Alzheimer's Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Alzheimer's Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Alzheimer's Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: North America: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: North America: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: United States: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: United States: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Canada: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Canada: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Asia Pacific: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Asia Pacific: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: China: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: China: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Japan: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Japan: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: India: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: India: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: South Korea: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: South Korea: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Australia: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Australia: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Indonesia: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Indonesia: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Others: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Europe: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Europe: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Germany: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Germany: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: France: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: France: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: United Kingdom: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: United Kingdom: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Italy: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Italy: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Spain: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Spain: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Russia: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Russia: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Others: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Latin America: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Latin America: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Brazil: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Brazil: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Mexico: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Mexico: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Others: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Middle East and Africa: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Middle East and Africa: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Global: Alzheimer's Drugs Industry: SWOT Analysis
  • Figure 74: Global: Alzheimer's Drugs Industry: Value Chain Analysis
  • Figure 75: Global: Alzheimer's Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Alzheimer's Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Alzheimer's Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 3: Global: Alzheimer's Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 4: Global: Alzheimer's Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Alzheimer's Drugs Market: Competitive Structure
  • Table 6: Global: Alzheimer's Drugs Market: Key Players